{"id":"W4380078644","doi":"10.1002/hon.3163_5","title":"NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; McGill University Health Centre","funders":"National Cancer Institute; Agenzia Italiana del Farmaco, Ministero della Salute; National Institutes of Health; Seagen; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Brentuximab vedotin; Neutropenia; Clinical endpoint; Oncology; Progression-free survival; Phases of clinical research; Randomized controlled trial; Chemotherapy; Lymphoma; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009850726,0.0005104552,0.0008542178,0.0001840427,0.0001703675,0.0005376452,0.0004331518,0.0003968104,0.00201868],"category_scores_gemma":[0.0006714887,0.0002147544,0.0007942981,0.0001751971,0.0003786301,0.0003856682,0.0001790893,0.001211468,0.0003226985],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005517537,"about_ca_system_score_gemma":0.0006576314,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007368483,"about_ca_topic_score_gemma":0.002106504,"domain_scores_codex":[0.9997875,0.0001105834,0.00001521505,0.00003064645,0.00002144862,0.00003460864],"domain_scores_gemma":[0.9995841,0.00009889923,0.0001060908,0.00002504072,0.00002663889,0.0001591782],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.694545,0.02465265,0.01559302,0.00137111,0.001633574,0.0001072519,0.0002901667,0.004143887,0.0363907,0.0002390906,0.007475016,0.2135586],"study_design_scores_gemma":[0.2759719,0.636235,0.06259931,0.0002325524,0.001967444,0.0005023348,0.0001530695,0.004161322,0.009621664,0.0003990639,0.008102597,0.00005372093],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957615,0.002737555,0.00009826596,0.0001887517,0.00006550596,0.0001283406,0.0003407539,0.000033578,0.0006458752],"genre_scores_gemma":[0.9962338,0.001572043,0.0003484819,0.0002602478,0.00006714817,0.000128447,0.0005412119,0.00001108108,0.0008376053],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00201868,"threshold_uncertainty_score":0.006753206,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0415212648976049,"score_gpt":0.3670687384005554,"score_spread":0.3255474735029505,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}